Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

Norihito Soga,Takumi Kageyama,Yuji Ogura,Tomomi Yamada,Norio Hayashi

Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

2015

Norihito Soga
Takumi Kageyama
Yuji Ogura
Tomomi Yamada
Norio Hayashi

Introduction: The efficacy of conversion from a luteinizing hormone-releasing hormone agonist to an antagonist was evaluated prospectively in patients with castra

Keywords:

Testosterone
Luteinizing hormone-releasing hormone agonist
Degarelix
Hormone
Antagonist
Medicine
Prostate cancer
Castration
Agonist
Pharmacology
Endocrinology
Internal medicine
in patient
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations